Cargando…

Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors

BACKGROUND: Colorectal cancer (CRC) is the second most common cause of cancer-related mortality worldwide with one in every five patients diagnosed with metastatic CRC (mCRC). In mCRC cases, the 5-year survival rate remains at approximately 14%, reflecting the lack of effectiveness of currently avai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kennedy, Susan A., Morrissey, Maria E., Dunne, Margaret R., O’Connell, Fiona, Butler, Clare T., Cathcart, Mary-Clare, Buckley, Amy M., Mehigan, Brian J., Larkin, John O., McCormick, Paul, Kennedy, Breandán N., O’Sullivan, Jacintha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532092/ https://www.ncbi.nlm.nih.gov/pubmed/33008336 http://dx.doi.org/10.1186/s12885-020-07430-y

Ejemplares similares

1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours
por: Butler, Clare T., et al.
Publicado: (2019)

1,4-dihydroxy quininib modulates the secretome of uveal melanoma tumour explants and a marker of oxidative phosphorylation in a metastatic xenograft model
por: Slater, Kayleigh, et al.
Publicado: (2023)

Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer
por: Murphy, Adrian G., et al.
Publicado: (2016)

The tumour microenvironment of the upper and lower gastrointestinal tract differentially influences dendritic cell maturation
por: Morrissey, Maria E., et al.
Publicado: (2020)

The Protein Secretome Is Altered in Rectal Cancer Tissue Compared to Normal Rectal Tissue, and Alterations in the Secretome Induce Enhanced Innate Immune Responses
por: Heeran, Aisling B., et al.
Publicado: (2021)

Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis
por: O’Connell, Jim, et al.
Publicado: (2022)

Expression of protein kinase C gamma promotes cell migration in colon cancer
por: Dowling, Catríona M., et al.
Publicado: (2017)

Protein kinase C beta II suppresses colorectal cancer by regulating IGF-1 mediated cell survival
por: Dowling, Catríona M., et al.
Publicado: (2016)

Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer
por: Burke, Lorraine, et al.
Publicado: (2016)

Characterisation of an Isogenic Model of Cisplatin Resistance in Oesophageal Adenocarcinoma Cells
por: Buckley, Amy M., et al.
Publicado: (2019)

Metformin is a metabolic modulator and radiosensitiser in rectal cancer
por: Buckley, Croí E., et al.
Publicado: (2023)

Radiation-induced Bystander Effect (RIBE) alters mitochondrial metabolism using a human rectal cancer ex vivo explant model
por: Heeran, Aisling B., et al.
Publicado: (2020)

Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib
por: Buckley, Amy M., et al.
Publicado: (2020)

Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinoma
por: Buckley, Amy M., et al.
Publicado: (2018)

Deciphering Combinations of PI3K/AKT/mTOR Pathway Drugs Augmenting Anti-Angiogenic Efficacy In Vivo
por: Sasore, Temitope, et al.
Publicado: (2014)

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023)

Survival outcomes after synchronous para‐aortic lymph node metastasis in colorectal cancer: A systematic review
por: Aylward, Conor, et al.
Publicado: (2022)

Application of PREVENA (Surgical Incision Protection System) in reducing surgical site infections following reversal of ileostomy or colostomy: the PRIC study protocol
por: Low, Ernest Z., et al.
Publicado: (2022)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment
por: Michielsen, Adriana J., et al.
Publicado: (2012)

Early vs. standard reversal ileostomy: a systematic review and meta-analysis
por: O’Sullivan, N. J., et al.
Publicado: (2022)

Gastrointestinal Stromal Tumours (GIST) of the Rectum: A Systematic Review and Meta-Analysis
por: Khan, Shaheer I., et al.
Publicado: (2022)

Sigmoid volvulus: definitive surgery is safe and should be considered in all instances
por: Hardy, Niall P., et al.
Publicado: (2021)

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX
por: Kiss, I., et al.
Publicado: (2017)

A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
por: Powell, Erin D., et al.
Publicado: (2009)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
por: Jafari, Abdosaleh, et al.
Publicado: (2023)

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
por: Matsunaga, Mototsugu, et al.
Publicado: (2016)

HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients
por: Dunne, Margaret R., et al.
Publicado: (2017)

Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment
por: Noonan, Sinead A., et al.
Publicado: (2018)

Six-Year Experience of a Nurse-Led Colorectal Cancer Follow-Up Clinic
por: Al Chalabi, Hasan, et al.
Publicado: (2014)

A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
por: Wang, Feng, et al.
Publicado: (2022)

FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer
por: Bertolini, F, et al.
Publicado: (2011)

Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
por: Salmi, Narimane, et al.
Publicado: (2014)

DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6
por: O'Connor, J P B, et al.
Publicado: (2011)

Prophylactic negative pressure wound therapy for closed laparotomy wounds: a systematic review and meta-analysis of randomised controlled trials
por: Boland, Patrick Anthony, et al.
Publicado: (2020)

LC3B globular structures correlate with survival in esophageal adenocarcinoma
por: El-Mashed, Shereen, et al.
Publicado: (2015)

Correction to: LC3B globular structures correlate with survival in esophageal adenocarcinoma
por: El-Mashed, Shereen, et al.
Publicado: (2019)

Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab
por: Otsu, Satoshi, et al.
Publicado: (2014)

Maternal topoisomerase II alpha, not topoisomerase II beta, enables embryonic development of zebrafish top2a(-/- )mutants
por: Sapetto-Rebow, Beata, et al.
Publicado: (2011)

Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
por: Takahashi, Takao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_42mreahiord35fmkcdv8rnrfnr